Nf light advantage sr x kit

Serum samples were stored at −80°C in the biobank La Fe following the protocols for standardization in biomarker measurements (12 (link)). sNFL levels were measured as in using the NF-light Advantage SR-X kit (SIMOA, Quanterix, Lexington, MA, United States) according to the manufacturer’s instructions. All coefficients of variation were less than 20%. sNFL were measured at the first clinical assessment (baseline) and quarterly until the end of the study period. sNFL Z-scores were calculated according to the free available online tool adjusting for age¹ (9 (link)).

Eight ml samples of peripheral blood collected from each DM1 patient were centrifuged within 3 h from sampling for 15 min at 3000 revolutions per minute (rpm) for serum separation, that was immediately stored at  – 80 °C. Frozen serum samples were then carried in dry ice to the Neuroimmunology Lab, Santa Lucia Foundation IRCCS, Rome (IT) for quantitative determination of NfL using an ultrasensitive immunoassay on the Single-Molecule Assay (SiMoA) platform [13 (link)]. Briefly, the assay was performed using the commercially available NF-light Advantage (SR-X) kit (Quanterix, item 103,400), run on the fully automated ultrasensitive SiMoA SR-X Analyzer (Quanterix Corporation, Massachusetts), following a two-step digital protocol. Calibrators (neat) and serum samples were measured in duplicate in accordance with the manufacturer’s instructions with appropriate standards and internal controls. Dynamic range of detection was from 0 pg/mL to 2000 pg/mL for measurements of serum samples. NfL levels from the DM1 group were compared with those obtained in a control group including 22 age- and sex-matched healthy subjects.